 Bleomycin
"Bleomycin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A complex of related glycopeptide antibiotics from Streptomyces verticillus consisting of bleomycin A2 and B2. It inhibits DNA metabolism and is used as an antineoplastic, especially for solid tumors.
| Descriptor ID |
D001761
|
| MeSH Number(s) |
D09.400.420.110 D12.644.233.110
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Bleomycin".
Below are MeSH descriptors whose meaning is more specific than "Bleomycin".
This graph shows the total number of publications written about "Bleomycin" by people in this website by year, and whether "Bleomycin" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 | | 1997 | 1 | 0 | 1 | | 1998 | 0 | 1 | 1 | | 1999 | 1 | 0 | 1 | | 2001 | 0 | 1 | 1 | | 2002 | 0 | 2 | 2 | | 2003 | 1 | 1 | 2 | | 2004 | 0 | 2 | 2 | | 2005 | 0 | 2 | 2 | | 2006 | 0 | 1 | 1 | | 2007 | 0 | 2 | 2 | | 2008 | 1 | 1 | 2 | | 2009 | 0 | 2 | 2 | | 2010 | 0 | 2 | 2 | | 2011 | 2 | 3 | 5 | | 2012 | 3 | 3 | 6 | | 2013 | 1 | 0 | 1 | | 2014 | 0 | 4 | 4 | | 2015 | 1 | 2 | 3 | | 2016 | 1 | 4 | 5 | | 2017 | 1 | 5 | 6 | | 2018 | 5 | 6 | 11 | | 2019 | 2 | 9 | 11 | | 2020 | 2 | 7 | 9 | | 2021 | 2 | 2 | 4 | | 2022 | 0 | 4 | 4 | | 2023 | 0 | 2 | 2 | | 2024 | 1 | 3 | 4 | | 2025 | 3 | 2 | 5 | | 2026 | 0 | 2 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Bleomycin" by people in Profiles.
-
Epeldegui M, Moser C, Choi Y, Borok M, Campbell TB, MacPhail P, Hosseinipour MC, Samaneka W, Nyirenda M, Kosgei J, Busakhala N, Martinez-Maza O, Krown SE. Serum Biomarkers in Advanced-Stage AIDS-Associated Kaposi Sarcoma in Resource Limited Settings. J Acquir Immune Defic Syndr. 2026 Apr 01; 101(4):416-423.
-
Flerlage JE, Feraco AM, Zhou Y, Zheng Y, Liang J, Lucas JT, Friedmann AM, Weinstein HJ, Yock TI, Shulkin B, Kaste SC, Marks LJ, Ehrhardt MJ, Dixon SB, Howard S, de Alarcon P, Luna-Fineman S, Geddis A, Larsen EC, Marcus K, Billett AL, Donaldson SS, Hudson MM, Metzger ML, Krasin MJ, Link MP. Dose-dense chemotherapy enables elimination of RT for the majority of low-risk pediatric Hodgkin lymphomas: PHC study HOD08. Blood. 2026 Mar 19; 147(12):1289-1301.
-
Signoretti C, Fatehi S, Drewes R, Cendali F, Dzieciatkowska M, D'Alessandro A, Bae Y, Gupte SA. Bleomycin-induced lung fibrosis and dysfunction is exacerbated by G6PD deficiency. Am J Physiol Lung Cell Mol Physiol. 2026 02 01; 330(2):L145-L158.
-
Kim SH, Nouws J, Ruwisch J, Woodard GA, Cooley J, Khoury J, Sun H, Doherty E, Piecychna M, Manning EP, Kang MJ, Bruscia EM, Wei H, Zhang Y, Yarovinsky TO, Hwa J, Zacharias WJ, Ingram J, Lee CG, Elias JA, Kaminski N, Redente EF, Herzog EL, Prasse A, Bucala R, Sauler M. Dysregulated alveolar type 2 epithelial cell proteostasis promotes fibrogenic macrophage migration inhibitory factor-CD74 signaling. Sci Transl Med. 2025 Dec 03; 17(827):eadr2277.
-
Bousamaki J, Rørbeck EA, Petersen AG, Korntner SH, Pors SE, Redente EF, Oró D, Salinas CG, Olsen RW, Simonsen U, Feigh M, Hansen HH. Distinct lung functional, histological and cell senescence signatures in the single and repetitive bleomycin mouse models of idiopathic pulmonary fibrosis. Physiol Rep. 2025 Sep; 13(18):e70560.
-
Brazee P, Allen N, Knipe R, Redente EF, Le Saux CJ. Peeling Back the Layers of the Bleomycin Model of Lung Fibrosis: Lessons Learned, Factors to Consider, and Future Directions. Semin Respir Crit Care Med. 2025 Aug; 46(4):330-346.
-
Hernández-Benítez J, López-Azcarraga A, Flerlage JE, Castellino S, Aristizabal P, Hoppe BS, Milgrom SA, de Paula MJA, Mailhot Vega RB. Curative Treatment of Pediatric Hodgkin Lymphoma With Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine and Consolidation Radiotherapy: A Systematic Review and Suggested Recommendations. JCO Glob Oncol. 2025 Jun; 11:e2400485.
-
King EM, Zhao Y, Moore CM, Steinhart B, Anderson KC, Vestal B, Moore PK, McManus SA, Evans CM, Mould KJ, Redente EF, McCubbrey AL, Janssen WJ. Gpnmb and Spp1 mark a conserved macrophage injury response masking fibrosis-specific programming in the lung. JCI Insight. 2024 Dec 20; 9(24).
-
Muraoka S, Brodie WD, Mattichak MN, Gurrea-Rubio M, Ikari Y, Foster C, Amin MA, Khanna N, Amin H, Campbell PL, Vichaikul S, Model EN, Omara MM, Petrovski S, Kozicki K, Amarista C, Webber A, Ali M, Palisoc PJ, Hervoso J, Ruth JH, Tsoi LC, Varga J, Gudjonsson JE, Khanna D, Fox DA, Tsou PS. Targeting CD13/Aminopeptidase N as a Novel Therapeutic Approach for Scleroderma Fibrosis. Arthritis Rheumatol. 2025 Jan; 77(1):80-91.
-
Burgy O, Mayr CH, Schenesse D, Fousekis Papakonstantinou E, Ballester B, Sengupta A, She Y, Hu Q, Melo-Narvaéz MC, Jain E, Pestoni JC, Mozurak M, Estrada-Bernal A, Onwuka U, Coughlan C, Parimon T, Chen P, Heimerl T, Bange G, Schmeck BT, Lindner M, Hilgendorff A, Ruppert C, Güenther A, Mann M, Yildirim AÖ, Eickelberg O, Jung AL, Schiller HB, Lehmann M, Burgstaller G, Königshoff M. Fibroblast-derived extracellular vesicles contain SFRP1 and mediate pulmonary fibrosis. JCI Insight. 2024 Aug 15; 9(18).
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|